Sunday, June 25  12 Total

Increased platelet activation demonstrated by elevated CD36 and P-selectin expression in one-year post-recovered COVID-19 patients

Increased platelet activation demonstrated by elevated CD36 and P-selectin expression in one-year post-recovered COVID-19 patients

June 25, 2023 | Samuel S.Y. Wang, M.D.; Tan Tock Seng Hospital; Singapore City, Singapore
Prevalence and risk factors for thromboembolism in women with sickle cell disease during pregnancy

Prevalence and risk factors for thromboembolism in women with sickle cell disease during pregnancy

June 25, 2023 | Shreya Agarwal, M.D.; Nationwide Children’s Hospital; Columbus, OH, U.S
Kupffer cells are required for platelet-mediated hepatocellular TPO generation

Kupffer cells are required for platelet-mediated hepatocellular TPO generation

June 25, 2023 | Danielle Karakas; University of Toronto; Toronto, Canada
Bleeding, FVIII activity, and safety three years after gene transfer with valoctocogene roxaparvovec: results from GENEr8-1

Bleeding, FVIII activity, and safety three years after gene transfer with valoctocogene roxaparvovec: results from GENEr8-1

June 25, 2023 | Johnny Mahlangu, M.D., M.Med.; University of the Witwatersrand; Johannesburg, South Africa

Rare germline loss-of-function variants in SERPINH1 (HSP47) are associated with increased risk of thrombosis

Rare germline loss-of-function variants in SERPINH1 (HSP47) are associated with increased risk of thrombosis

June 25, 2023 | Amelia Haj, M.D., Ph.D.; Massachusetts General Hospital; Boston, MA, U.S.

HDAC6 regulates endothelial dysfunction in thromboembolic venous disease

HDAC6 regulates endothelial dysfunction in thromboembolic venous disease

June 25, 2023 | Marion Pilard; National Institute of Health and Medical Research (INSERM); Brest, France

Emicizumab prophylaxis instead of immunosuppressive therapy in patients with acquired hemophilia A (AHA)

Emicizumab prophylaxis instead of immunosuppressive therapy in patients with acquired hemophilia A (AHA)

June 25, 2023 | Andreas Tiede, M.D., Ph.D.; Hannover Medical School; Hannover, Germany

Monday, June 26  10 Total

Andexanet alfa is associated with lower in-hospital mortality compared to 4-factor prothrombin complex concentrate in patients with factor Xa inhibitor-related major bleeding

Andexanet alfa is associated with lower in-hospital mortality compared to 4-factor prothrombin complex concentrate in patients with factor Xa inhibitor-related major bleeding

June 26th, 2023 | Paul P. Dobesh, Pharm.D.; University of Nebraska Medical Center, College of Pharmacy; Omaha, NE, U.S.

Platelet-derived integrin and tetraspanin-enriched tethers (PITTs) orchestrate neutrophil recruitment and drive pulmonary thrombo-inflammation

Platelet-derived integrin and tetraspanin-enriched tethers (PITTs) orchestrate neutrophil recruitment and drive pulmonary thrombo-inflammation

June 26, 2023 | Denise Johnson, M.Sc.; Institute of Experimental Biomedicine I; University Hospital Würzburg; Würzburg, Germany
Evaluation of the burden of bone fractures in people living with hemophilia: a registry-based case-control study

Evaluation of the burden of bone fractures in people living with hemophilia: a registry-based case-control study

June 26, 2023 | Federico Germini, M.D., Ph.D.; McMaster University; Hamilton, Canada
The Throm-PED Registry: epidemiology and treatment of adolescent thrombosis

The Throm-PED Registry: epidemiology and treatment of adolescent thrombosis

June 26, 2023 | Heleen Van Ommen, M.D, Ph.D.; Erasmus MC Sophia Children’s Hospital; Rotterdam, The Netherlands
Pharmacological targeting of coagulation factor XI attenuates experimental autoimmune encephalomyelitis in mice

Pharmacological targeting of coagulation factor XI attenuates experimental autoimmune encephalomyelitis in mice

June 26, 2023 | Tia C. L. Kohs, Ph.D.; Oregon Health and Science University; Portland, OR, U.S.
Structural identification of the factor XII - uPAR binding interface for selective drug development

Structural identification of the factor XII - uPAR binding interface for selective drug development

June 26, 2023 | Dillon Bohinc, B.S.; Case Western Reserve University; Cleveland, OH, U.S.
Hypoalbuminemia increases clot fibrin network density and impairs fibrinolysis during glomerular proteinuria

Hypoalbuminemia increases clot fibrin network density and impairs fibrinolysis during glomerular proteinuria

June 26, 2023 | Amanda P. Waller, Ph.D., M.Sc.; Center for Clinical and Translational Research; Nationwide Children’s Hospital; Columbus, OH, U.S.